Positive feedback from FDA on strategy to lift clinical hold
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The FDA has confirmed alignment with Neurizon's plan to conduct two preclinical pharmacokinetic studies, which have already been completed ahead of schedule. Neurizon plans to submit a Complete Response to the FDA in the near future, aiming to resolve the clinical hold and participate in the HEALEY ALS Platform Trial. The company remains committed to advancing treatments for neurodegenerative diseases, particularly amyotrophic lateral sclerosis.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
- Neurizon Enters Global Licensing Agreement with Elanco
- Neurizon develops liquid formulation of NUZ-001
- NUZ-001 Shows Significant Blood-Brain Barrier Penetration
- NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
Later from Neurizon Therapeutics
- Neurizon Submits Clinical Hold Complete Response to FDA
- Neurizon Secures Loan Against 2025 R&D Tax Rebate
- FDA Review Timeline Extended for NUZ-001 IND Clinical Hold
- NUZ-001 Shows Long-Term Safety and Efficacy Signals in OLE
- Appendix 4E and 2025 Annual Report
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics